MKI67 Gene Digestive System Neuroendocrine Tumor clinical trials
4 active Digestive System Neuroendocrine Tumor trials that test for MKI67 Gene in their eligibility criteria. Describe your situation to see which ones look like a fit.
- 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry
- Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
- Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
- Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
← All Digestive System Neuroendocrine Tumor trials
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.